Expanding Liver Transplant Immunosuppression Minimization Via Everolimus
NCT ID: NCT06280950
Last Updated: 2025-05-31
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE2
340 participants
INTERVENTIONAL
2024-09-12
2029-06-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Efficacy and Safety of Concentration-controlled Everolimus to Eliminate or to Reduce Tacrolimus Compared to Tacrolimus in de Novo Liver Transplant Recipients
NCT00622869
Everolimus Monotherapy as Immunosuppression After Liver Transplant
NCT04063865
Biomarkers Predicting Successful Tacrolimus Withdrawal and Everolimus (Zortress) Monotherapy Early After Liver Transplantation
NCT02736227
Extension Study to Evaluate the Long-term Efficacy and Safety of Everolimus in Liver Transplant Recipients
NCT01150097
Everolimus Post Orthotopic Liver Transplant
NCT01998789
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Interventional Group 1
Participants in this group will slowly reduce their dose of tacrolimus and continue everolimus as their only immunosuppression medication.
Everolimus
* The first step is the addition of everolimus to participants in this group pre-randomization.
* Participants on a mycophenolate compound will stop taking it within 7 days of initiating everolimus, either by immediate discontinuation or a 7-day taper.
* Participants taking prednisone will taper off prednisone by 6 months post-transplant.
* The second step is tacrolimus minimization and withdrawal to everolimus monotherapy in this group after randomization.
Tacrolimus (continued reduction)
* Participants randomized in this cohort will have their tacrolimus dose reduced by 50% following randomization.
* They will maintain this daily dose for 4 weeks/1 month (28-30 days). Tacrolimus withdrawal will occur in intervals of 30 days or 4 weeks.
* Each subsequent reduction will be based on LFT stability over the prior time interval before the next reduction
Interventional Group 2
Participants in this group will continue to take reduced Tacrolimus and Everolimus IS regimen.
Tacrolimus (maintain 50% reduction)
\- Participants randomized in this cohort maintain initial reduced dose of Tacrolimus and everolimus for study duration.
Everolimus
* The first step is the addition of everolimus to participants in the interventional group pre-randomization.
* Participants on a mycophenolate compound will stop taking it within 7 days of initiating everolimus, either by immediate discontinuation or a 7-day taper.
* Participants taking prednisone will taper off prednisone by 6 months post-transplant.
* The second step is to continue on the reduced tacrolimus and everolimus regimen.
Observational Group
Participants in this group could not tolerate the addition of everolimus. These participants will not be randomized.
* Participants in this group will stop taking everolimus.
* Participants in this group will resume taking their tacrolimus +/- mycophenolate compound and prednisone immunosuppression regimen.
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Everolimus
* The first step is the addition of everolimus to participants in this group pre-randomization.
* Participants on a mycophenolate compound will stop taking it within 7 days of initiating everolimus, either by immediate discontinuation or a 7-day taper.
* Participants taking prednisone will taper off prednisone by 6 months post-transplant.
* The second step is tacrolimus minimization and withdrawal to everolimus monotherapy in this group after randomization.
Tacrolimus (continued reduction)
* Participants randomized in this cohort will have their tacrolimus dose reduced by 50% following randomization.
* They will maintain this daily dose for 4 weeks/1 month (28-30 days). Tacrolimus withdrawal will occur in intervals of 30 days or 4 weeks.
* Each subsequent reduction will be based on LFT stability over the prior time interval before the next reduction
Tacrolimus (maintain 50% reduction)
\- Participants randomized in this cohort maintain initial reduced dose of Tacrolimus and everolimus for study duration.
Everolimus
* The first step is the addition of everolimus to participants in the interventional group pre-randomization.
* Participants on a mycophenolate compound will stop taking it within 7 days of initiating everolimus, either by immediate discontinuation or a 7-day taper.
* Participants taking prednisone will taper off prednisone by 6 months post-transplant.
* The second step is to continue on the reduced tacrolimus and everolimus regimen.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Adult (age greater than or equal to 18 years of age at time of informed consent) recipient of first liver transplant alone (de novo)
3. Estimated glomerular filtration rate \>=30 ml/min/1.73m\^2 at enrollment using the CKD-EPI 2021 equation
4. Treatment with tacrolimus therapy, with or without mycophenolic acid derivatives and/or corticosteroids
5. Female subjects of childbearing potential with negative pregnancy test upon study entry
6. All subjects of reproductive potential agreeing to use contraception for the duration of the study
7. Previous vaccination or documented immunity to varicella, measles, hepatitis B, pneumococcus, influenza, zoster (if \>=19 years old), and 2019-nCoV (COVID-19) as outlined in the DAIT Vaccination Guideline
Exclusion Criteria
2. Active unresolved systemic viral, bacterial, fungal, or parasitic infection requiring oral or intravenous anti-infective therapy
3. History of autoimmune liver disease including autoimmune hepatitis, primary sclerosing cholangitis, and/or primary biliary cirrhosis, or other contraindications to drug withdrawal
4. History of non-hepatic autoimmune disease requiring current or future systemic immunosuppressive therapy other than per study protocol
5. History post-transplant of Hepatic Artery Thrombosis or Portal Vein Thrombosis.
6. History of recurrent cirrhosis after liver transplantation.
7. Chronic use of systemic glucocorticoids, biological immunomodulatory therapy, or other immunosuppressive agents other than per study protocol
8. History of hepatitis B or C virus infection with detectable viral PCR at enrollment
9. History of prior organ transplantation (liver or other type)
10. History of \>= 2 biopsy-proven acute cellular rejection episodes of any severity, \>=1 moderate to severe rejection episode (histologically defined or requiring lymphodepletion therapy), or \>= 1 antibody- mediated rejection episode
11. Active treatment with any mTOR-inhibitor agent (everolimus, sirolimus)
12. Contraindication to treatment with everolimus (open wound or wound infection; urine protein: creatinine ratio \> 0.5; significant pancytopenia (any of the following: WBC \<1.5 K/uL or ANC \<1000 cells/uL or actively being treated with GCSF; Hb \<8.0; platelet count \<50K); serum triglycerides \> 1000 mg/dL; other per PI)
13. Abnormal liver function tests on study entry: Total Bilirubin (TB)\>1.5 mg/dL and Direct Bilirubin (DB) \>1.0 mg/dL, Alkaline Phosphatase (AP) \>200 U/L, and Alanine Aminotransaminase (ALT)\>60 U/L
14. Pregnant on enrollment or plan to become pregnant during the study period
15. Participation in another clinical trial that would interfere with this study's procedures and intervention:
1. Use of investigational biologic or drug (within 8 weeks of study enrollment)
2. Additional blood collection that would exceed research blood draw limits
3. Any other procedure or intervention, in the investigator's opinion would interfere with this study
16. Received live attenuated vaccine(s) within 2 months of enrollment
17. Current, diagnosed, mental illness or current, diagnosed, or self-reported drug or alcohol abuse that, in the opinion of the investigator, would interfere with the participant's ability to comply with study requirements or that may impact the quality or interpretation of the data obtained from the study
18. Past or current medical problems or findings from physical examination or laboratory testing that are not listed above, which, in the opinion of the investigator, may pose additional risks from participation in the study, may interfere with the participant's ability to comply with study requirements or that may impact the quality or interpretation of the data obtained from the study.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Justin Boike, MD
Role: PRINCIPAL_INVESTIGATOR
Northwestern University Feinberg School of Medicine: Transplantation
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Mayo Clinic Hospital Arizona (Site #: 71144)
Phoenix, Arizona, United States
University of California, San Francisco (Site #: 71108)
San Francisco, California, United States
Northwestern University (Site #: 71110)
Chicago, Illinois, United States
Icahn School of Medicine at Mount Sinai (Site #: 71115)
New York, New York, United States
Duke University Medical Center (Site #: 71139)
Durham, North Carolina, United States
University of Pennsylvania (Site #: 71111)
Philadelphia, Pennsylvania, United States
University of Pittsburgh Medical Center (Site #: 71170)
Pittsburgh, Pennsylvania, United States
Baylor Medical Center (Site #: 71153)
Dallas, Texas, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
DAIT CTOT-43
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.